huCART-meso + VCN-01 for Pancreatic Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on high-dose corticosteroids or certain immunotherapy drugs, you may need to stop or adjust them before participating.
What data supports the effectiveness of the huCART-meso + VCN-01 treatment for pancreatic cancer?
Research shows that T cells engineered with chimeric antigen receptors (CAR T cells) can target and kill cancer cells in pancreatic cancer models, particularly those expressing mesothelin, a protein often found in these tumors. These CAR T cells have been effective in reducing tumor growth and eliminating metastases in animal studies, suggesting potential for treating pancreatic cancer in humans.12345
Is the huCART-meso + VCN-01 treatment safe for humans?
The research on CAR T cell therapy, which includes huCART-meso, suggests it can be effective against pancreatic cancer cells, but there are concerns about safety, particularly 'on-target, off-tumor' toxicity, which means the treatment might affect healthy cells as well. The studies focus on improving safety by using different methods to engineer the cells, but specific safety data for humans is not detailed in the available research.12567
What makes the huCART-meso + VCN-01 treatment unique for pancreatic cancer?
The huCART-meso + VCN-01 treatment is unique because it combines genetically modified immune cells (huCART-meso) with an oncolytic virus (VCN-01) to target pancreatic cancer, offering a novel approach compared to traditional chemotherapy. This combination aims to enhance the immune system's ability to recognize and destroy cancer cells while the virus selectively infects and kills tumor cells.3891011
What is the purpose of this trial?
This trial is testing a combination of modified immune cells and a virus-based therapy in patients who may not have responded to other treatments. The immune cells are designed to target and destroy cancer cells, while the virus helps by killing cancer cells and enhancing the immune response. The virus therapy has been approved for the treatment of metastatic melanoma.
Research Team
Janos Tanyi, MD, PhD
Principal Investigator
University of Pennsylvania
Eligibility Criteria
This trial is for adults with specific advanced cancers: unresectable or metastatic pancreatic adenocarcinoma, and persistent or recurrent serous epithelial ovarian cancer. Participants must have tried at least one standard chemotherapy, be in good physical condition (ECOG 0-1), not need oxygen therapy, and have no other active invasive cancers or significant health issues like heart disease, autoimmune diseases requiring steroids, or certain infections.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VCN-01 and huCART-meso cells in a 3+3 dose escalation design. Cohort 1 receives VCN-01 on Day 0 and huCART-meso on Day 14. Cohort 2 receives a higher dose of VCN-01 on Day 0 and huCART-meso on Day 14. Cohort -1, if needed, receives huCART-meso on Day 0 and VCN-01 on Day 10.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with formal DLT assessments performed by the Clinical PI and Sponsor Medical Director.
Open-label extension (optional)
Participants may opt into continuation of treatment long-term if the dose combination is identified as the recommended phase 2 dose (RP2D).
Treatment Details
Interventions
- huCART-meso Cells
- VCN-01
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
Theriva Biologics
Collaborator
Theriva Biologics SL
Industry Sponsor
VCN Biosciences, S.L.
Industry Sponsor